GlassScriptPhysician profile
Leslie E Wilson
NPI 1861466815
$10,535.21
in general payments reported to CMS, 2019-2025
29 companies · $2,230 in 2025
The $2,230 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $572 · 2020: $718 · 2021: $1,370 · 2022: $1,556 · 2023: $2,144 · 2024: $1,945 · 2025: $2,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,318.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,104.91 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $2,009.02 | 2019-2025 | Enbrel, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $766.04 | 2021-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $705.51 | 2019-2025 | Benlysta |
| Janssen Biotech, INC. | $642.60 | 2020-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $570.56 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $569.57 | 2019-2024 | Taltz |
| Novartis Pharmaceuticals Corporation | $519.12 | 2019-2025 | |
| Tersera Therapeutics LLC | $488.70 | 2022-2024 | Quzyttir |
| Horizon Therapeutics Plc | $465.44 | 2019-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $383.77 | 2019-2025 | Orencia |
| Organon LLC | $224.83 | 2022-2025 | Hadlima, Renflexis |
| Ani Pharmaceuticals, INC. | $199.08 | 2025 | Purified Cortrophin Gel |
| Pfizer INC. | $143.73 | 2020-2022 | |
| Pacira Therapeutics, INC. | $125.07 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $115.97 | 2023-2024 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $107.59 | 2022-2025 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.27 | 2019-2024 | Ofev, Cyltezo |
| Genentech USA, INC. | $67.50 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $46.36 | 2024 | Arcalyst |
| Spectrum Pharmaceuticals INC. | $33.57 | 2023 | Rolvedon |
| Merck Sharp & Dohme LLC | $29.91 | 2024 | Keytruda |
| Daiichi Sankyo INC. | $26.04 | 2023 | Enhertu |
| Stemline Therapeutics INC. | $22.26 | 2025 | Orserdu |
| Fresenius Kabi USA, LLC | $22.00 | 2024 | |
| Puma Biotechnology, INC. | $19.03 | 2022 | |
| Mylan Institutional INC. | $17.52 | 2023 | Hulio |
| Takeda Pharmaceuticals U.S.A., INC. | $15.29 | 2019 | |
| Blue Earth Diagnostics | $14.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.